Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy
Conditions: Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting Interventions: Drug: Tecfidera (BG12); Drug: Gilenya; Drug: Tysabri®; Drug: Avonex/Betaseron/Copaxone/Rebif; Procedure: Hematopoietic stem cell transplantation (HSCT) Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust Recruiting - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 21, 2016 Category: Research Source Type: clinical trials
EPID Multiple Sclerosis Pregnancy Study
Condition: Multiple SclerosisInterventions: Drug: Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG; Drug: Extavia (interferon beta-1b), Novartis Pharma AG; Drug: Rebif (interferon beta-1a), Merck Serono Europe Ltd; Drug: Plegridy (peginterferon beta-1a), Biogen Idec Ltd; Drug: Avonex (interferon beta-1a), Biogen Idec Ltd; Drug: MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046); Other: No MSDMDs therapy (control)Sponsors: Bayer; EPID Research; Biogen; Merck Serono Europe Ltd; Novartis PharmaceuticalsNot yet recruiting - verified April 2016 (Source...
Source: ClinicalTrials.gov - April 20, 2016 Category: Research Source Type: clinical trials
